Laura F Newell1, Kelsea M Shoop2, Rebekah J Knight2, Sara N Murray2, Rogelyn P Kwock3, Carol E Jacoby3, Susan Slater3, Bryon E Allen3, Casondra Ottowa4, Brad Cota5, Peggy L Appel6, Rachel J Cook3, Richard T Maziarz3, Gabrielle Meyers3. 1. Knight Cancer Institute, Hematology and Medical Oncology, Oregon Health & Science University, Portland, Oregon, USA. Electronic address: newelll@ohsu.edu. 2. Hematopoietic Cell Processing Laboratory, Hospital and Clinics, Oregon Health & Science University, Portland Oregon, USA. 3. Knight Cancer Institute, Hematology and Medical Oncology, Oregon Health & Science University, Portland, Oregon, USA. 4. Apheresis Unit, Hospital and Clinics, Oregon Health & Science University, Portland Oregon, USA. 5. Hospital and Clinics Financial Services, Oregon Health & Science University, Portland Oregon, USA. 6. Northwest Marrow Transplant Program, Oregon Health & Science University, Portland Oregon, USA.
Abstract
BACKGROUND: Guidelines recommend treatment with 4-5 days of granulocyte colony-stimulating factor (G-CSF) for optimal donor peripheral blood progenitor cell (PBPC) mobilization followed by day 5 collection. Given that some autologous transplant recipients achieve adequate collection by day 4 and the possibility that some allogeneic donors may maximally mobilize PBPC before day 5, a feasibility study was performed evaluating day 4 allogeneic PBPC collection. METHODS: HLA-matched sibling donors underwent collection on day 4 of G-CSF for peripheral blood (PB) CD34+ counts ≥0.04 × 106/mL, otherwise they underwent collection on day 5. Those with inadequate collected CD34+ cells/kg recipient weight underwent repeat collection over 2 days. Transplant and PBPC characteristics and cost analysis were compared with a historical cohort collected on day 5 per our prior institutional algorithm. RESULTS: Of the 101 patient/donor pairs, 50 (49.5%) had adequate PBPC collection on day 4, with a median PB CD34+ cell count of 0.06 × 106/mL. Day 4 donors were more likely to develop bone pain and require analgesics. Median collected CD34+ count was significantly greater, whereas total nucleated, mononuclear and CD3+ cell counts were significantly lower, at time of transplant infusion for day 4 versus other collection cohorts. There were no significant differences in engraftment or graft-versus-host disease. Cost analysis revealed 6.7% direct cost savings for day 4 versus historical day 5 collection. DISCUSSION: Day 4 PB CD34+ threshold of ≥0.04 × 106/mL identified donors with high likelihood of adequate PBPC collection. Day 4 may be the optimal day of collection for healthy donors, without adverse effect on recipient transplant outcomes and with expected cost savings.
BACKGROUND: Guidelines recommend treatment with 4-5 days of granulocyte colony-stimulating factor (G-CSF) for optimal donor peripheral blood progenitor cell (PBPC) mobilization followed by day 5 collection. Given that some autologous transplant recipients achieve adequate collection by day 4 and the possibility that some allogeneic donors may maximally mobilize PBPC before day 5, a feasibility study was performed evaluating day 4 allogeneic PBPC collection. METHODS: HLA-matched sibling donors underwent collection on day 4 of G-CSF for peripheral blood (PB) CD34+ counts ≥0.04 × 106/mL, otherwise they underwent collection on day 5. Those with inadequate collected CD34+ cells/kg recipient weight underwent repeat collection over 2 days. Transplant and PBPC characteristics and cost analysis were compared with a historical cohort collected on day 5 per our prior institutional algorithm. RESULTS: Of the 101 patient/donor pairs, 50 (49.5%) had adequate PBPC collection on day 4, with a median PB CD34+ cell count of 0.06 × 106/mL. Day 4 donors were more likely to develop bone pain and require analgesics. Median collected CD34+ count was significantly greater, whereas total nucleated, mononuclear and CD3+ cell counts were significantly lower, at time of transplant infusion for day 4 versus other collection cohorts. There were no significant differences in engraftment or graft-versus-host disease. Cost analysis revealed 6.7% direct cost savings for day 4 versus historical day 5 collection. DISCUSSION: Day 4 PB CD34+ threshold of ≥0.04 × 106/mL identified donors with high likelihood of adequate PBPC collection. Day 4 may be the optimal day of collection for healthy donors, without adverse effect on recipient transplant outcomes and with expected cost savings.
Authors: J P Panse; S Heimfeld; K A Guthrie; M B Maris; D G Maloney; B B Baril; M-T Little; T R Chauncey; B E Storer; R Storb; B M Sandmaier Journal: Br J Haematol Date: 2005-03 Impact factor: 6.998
Authors: Sergio Giralt; Luciano Costa; Jeffrey Schriber; John Dipersio; Richard Maziarz; John McCarty; Paul Shaughnessy; Edward Snyder; William Bensinger; Edward Copelan; Chitra Hosing; Robert Negrin; Finn Bo Petersen; Damiano Rondelli; Robert Soiffer; Helen Leather; Amy Pazzalia; Steven Devine Journal: Biol Blood Marrow Transplant Date: 2013-10-17 Impact factor: 5.742
Authors: Michael A Pulsipher; Pintip Chitphakdithai; John P Miller; Brent R Logan; Roberta J King; J Douglas Rizzo; Susan F Leitman; Paolo Anderlini; Michael D Haagenson; Seira Kurian; John P Klein; Mary M Horowitz; Dennis L Confer Journal: Blood Date: 2009-02-03 Impact factor: 22.113